Comparative, Randomized,, Single Dose, Open-label, Crossover Bioequivalence Study of LOSANET AM PLUS 10mg/100mg/12.5 mg Tablets (One Tablet) of (PHARMALINE, Lebanon) Versus NORVASC 10mg Tablets (One Tablet) of (Pfizer Canada Inc., Kirkland (Quebec)) and HYZAAR 100mg/12.5 Tablets (One Tablet) of (Merck Sharp & Dohme, Quimica de Puerto Rico, Inc, Road 2 Km. 60.3, Sabana Hoyos, Arecibo, PR 00688 for Merck Sharp & Dohme B.V. Haarlem, The Netherlands) in Healthy Subjects Under Fasting Conditions.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- To assess the bioequivalence of Test oral formulation of LOSANET AM PLUS versus References NORVASC and HYZAAR.
研究概览
简要总结
To assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Amlodipine ,Losartan, Carboxylic acid losartan metabolite & Hydrochlorothiazide in plasma and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects.
- •Ethnic Group: Arab & Mediterranean
- •Race: Mixed skin (white & black skin people).
- •Age 18-50 years
- •Body-mass index 18.5 to 30.0 kg/m2 inclusive (minimum of 50 kg weight).
- •Subject is available for the whole study period and gave written informed consent
- •Physical examination within normal ranges
- •All laboratory screening results within the normal range, or being assessed as clinically non-significant by the attending physician
- •Vital signs within normal ranges.
- •Kidney function test, Liver function test should be within normal ranges.
- •Pre dosing blood pressure more than 110/70 mmHg.
排除标准
- •Women of childbearing potential, pregnant and lactating women.
- •Ethnic Group (Non- Arab &/ or Non- Mediterranean)
- •History of severe allergy or allergic reactions to study drug or related drugs or heparin
- •Known history or presence of food allergies, or any surgical or medical condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
- •History of serious illness that can impact fate of drugs
- •Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, liver or kidney disease, unless judged not clinically significant by the Principal Investigator, or medical designate
- •Clinically significant illness 4 weeks before study Period I
- •Serious mental disease, drug, alcohol, solvents or caffeine abuse, smoking.
- •Regular use of medication
- •Having taken medication that could affect the investigated drug product: a) Regular consumption of drugs during the two weeks prior to study initiation day, b) consumption of enzyme stimulating or inhibiting drugs (e.g. Barbiturates, Carbamazepine, Phenytoin, Amphetamine, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone) during one month before the study initiation
- •Presence of any significant physical or organ abnormality
- •Donation of 1) at least 400 ml of blood within 60 days, or 2) more than 150 ml of blood within 30 days, or 3) more than 100 ml blood plasma or platelets within 14 days before study Period I
- •Participation in another bioequivalence study within 80 days prior to the start of this study Period I
- •Following a special diet (e.g. vegetarian) or dieting one month before the study initiation.
- •Prior history of hypersensitivity to Amlodipine besylate, Losartan Potassium & Hydrochlorothiazide.
- •Consumption of grapefruit or grapefruit containing products within 7 days of drug administration
- •Ingestion of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
- •Exhausting physical exercise in the last 48 hours (e.g. weight lifting) or any recent significant change in dietary or exercise habits.
- •Any significant clinical abnormality including HBsAg, HCV, and HIV
- •Abnormal vital signs.
- •Abnormal Kidney or Liver function tests.
- •Vomiting, Diarrhea.
- •Pre dosing blood pressure less than 110/70 mmHg
- •Positive test for elicit drugs and alcohol prior to dosing in each period.
研究组 & 干预措施
LOSANET AM PLUS (10/100/12.5 mg) of PHARMALINE, Lebanon
Subjects will be fasted overnight and receive one tablet by mouth in accordance with randomization table, and blood samples will be taken at specified intervals over 3 days
intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA
干预措施: Amlodipin, losartan, HCTZ (Drug)
NORVASC & HYZAAR (100/12.5 mg)
Subjects will be fasted overnight and receive one tablet of Norvasc &HYZAAR by mouth in accordance with randomization table, and blood samples will be taken over 3 days
intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA
干预措施: Amlodipin, losartan, HCTZ (Drug)
结局指标
主要结局
To assess the bioequivalence of Test oral formulation of LOSANET AM PLUS versus References NORVASC and HYZAAR.
时间窗: 9 weeks
To assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Amlodipine ,Losartan, Carboxylic acid losartan metabolite \& Hydrochlorothiazide in plasma and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation. Cmax Ratio: Scaled average bioequivalence will be performed. Bioequivalence limits will be defined and widened according to the variance of σw2 within subject variability for the reference based on Amlodipine, Losartan, \& Hydrochlorothiazide AUC Ratio: The 90% confidence interval for this measure lies within an acceptance range of 80.00% - 125.00% based on Losartan, \& Hydrochlorothiazide AUC0-72 Ratio: The 90% confidence interval for this measure lies within an acceptance range of 80.00 - 125.00 % based on Amlodipine Carboxylic acid Losartan metabolite will be considered as supportive data
次要结局
未报告次要终点